IBEX Ltd IBEX 深 沪
等待开盘 09-01 09:30:00 美东时间
38.46
+0.340
+0.89%
华盛通- 最 高38.84
- 今 开37.76
- 成交量 11.87万股
- 最 低 37.345
- 昨 收 38.12
- 总市值 5.15亿
- 52周最高 42.99
- 市盈率 静 16.33
- 换手率 0.89%
- 52周最低 25.94
- 委 比 86.13%
- 总股本 1338.91万
- 历史最高 42.99
- 量 比 1.36
- 振 幅 3.92%
- 历史最低 9.27
- 每 手 1
- 风险率 4.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多IBEX Limited to Announce Fourth Quarter and Fiscal Year 2026 Financial Results on September 10, 2026
IBEX Limited, a global leader in outsourced business services and AI-powered customer experience solutions, announced it will release its fourth quarter and fiscal year 2026 financial results on Thursday, September 10, 2026, after market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results, recent developments, and business outlook.
08-27 20:15
从“被遗忘的角落”到“避险新贵”：欧股财报季惊艳全场，盈利增长22%创四年新高
强劲财报季与油价回落正共同提升欧洲股市的避险吸引力，与此同时，投资者正重返欧洲市场，将其视为对冲高波动全球科技股的选择。
08-10 11:54
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
Grifols has completed the clinical portion of its SPARTA phase 3 trial, evaluating the efficacy and safety of Prolastin-C in treating emphysema caused by alpha-1 antitrypsin deficiency. The trial, the largest of its kind, involved 345 participants across 16 countries and used CT densitometry to measure lung tissue loss. Topline results are expected by late 2026. Grifols remains committed to advancing innovation in alpha-1 treatment through resear...
08-10 11:00
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
Grifols has initiated two Phase 3 trials to expand U.S. labels for its immunoglobulin therapies, GAMUNEX-C and XEMBIFY. The SIGMA trial evaluates GAMUNEX-C in preventing infections in patients with secondary immunodeficiency, particularly those with blood cancers. The XPERT trial compares XEMBIFY's efficacy and safety to GAMUNEX-C in treating Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Both studies aim to provide more treatm...
07-16 12:00
全球科技上半年迎牛市狂欢 最大赢家却不在美国
科技行业在2026年上半年成为全球股市的明显赢家。尽管6月末遭遇一轮猛烈抛售，美国大型科技股录得可观涨幅，然而其表现仍整体落后于海外同业。
07-02 11:15
ibex Honors the Winners of the 5th Annual CX Leadership Awards at CCW Las Vegas
LAS VEGAS, July 01, 2026 (GLOBE NEWSWIRE) -- ibex, a global leader in outsourced business services and AI-powered customer experience solutions, announced the winners of the 2026 CX Leadership Awards. These awards recognize top CX innovators and leaders worldwide. This year’s winners, selected from a strong list of professionals, were honored at ibex’s Fifth Annual CX Leadership Awards Dinner during Customer Contact Week (CCW) in Las Vegas. Winne...
07-01 13:00
